NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High

Company highlights growing contracted project activity, expanding pharmaceutical engagements, initial commercial activation of CRO channel and continued scientific progress

TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc . (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.

Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract research organizations (“CROs”). The Company has added a new late-stage biopharmaceutical engagement, expanded its clinical-development leadership, continued building its scientific evidence base and, subsequent to the end of its third fiscal quarter, announced the first commercial project generated through its CRO channel.

A welcome email is on its way. If you don't see it, please check your junk folder.

“We are genuinely excited about the stage NetraMark has reached. Years of focused technology development, scientific validation and industry engagement are now translating into broader commercial adoption,” said George Achilleos, Chief Executive Officer of NetraMark. “Our dual path strategy working directly with pharmaceutical sponsors while embedding NetraAI within CRO relationships that can scale across multiple clinical programs is delivering clear results, and we are proud of the tangible progress we are seeing on both fronts.”